1. Home
  2. MGNX vs AP Comparison

MGNX vs AP Comparison

Compare MGNX & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.95

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo Ampco-Pittsburgh Corporation

AP

Ampco-Pittsburgh Corporation

HOLD

Current Price

$6.62

Market Cap

138.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
AP
Founded
2000
1929
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
138.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MGNX
AP
Price
$2.95
$6.62
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$3.40
N/A
AVG Volume (30 Days)
1.3M
322.6K
Earning Date
06-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.75
52 Week High
$3.50
$9.99

Technical Indicators

Market Signals
Indicator
MGNX
AP
Relative Strength Index (RSI) 67.59 37.95
Support Level $1.45 $2.42
Resistance Level $3.50 $9.84
Average True Range (ATR) 0.22 0.84
MACD 0.07 -0.41
Stochastic Oscillator 67.46 25.81

Price Performance

Historical Comparison
MGNX
AP

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About AP Ampco-Pittsburgh Corporation

Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.

Share on Social Networks: